Apricus Elects Kleanthis G. Xanthopoulos, Ph.D. as New Chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
Apricus Biosciences (APRI) Appoints Kleanthis Xanthopoulos as Chairman
December 11, 2013 7:07 AM ESTApricus Biosciences, Inc. (Nasdaq: APRI) announced that Kleanthis G. Xanthopoulos, Ph.D. has been elected as Chairman of the Company's Board of Directors. Dr. Xanthopoulos succeeds Mr. Rusty Ray in the Chairman role. Mr. Ray will continue to serve as a Director and will assume key roles on the Company's audit, compensation and corporate governance committees of the Board. Dr. Xanthopoulos has been a member of the Apricus Board since 2011.
"I am honored to be elected Chairman of the Apricus Board of Directors during this pivotal point in the Company's evolution," said Dr. Xanthopoulos.... More
